Clinical trialsCompany release

Eloxx doses first Alport patients in Phase 2b and wins FDA IND clearance in ADPKD

🇺🇸 Eloxx Pharmaceuticals, Inc. (ELOX) · Mon 16 Nov 2026

Eloxx Pharmaceuticals reported Q3 2026 results, with exaluren now in a Phase 2b Alport trial, an FDA-cleared ADPKD study, and cash guided into 2028.

Eloxx Pharmaceuticals reported its third-quarter 2026 results on 16 November, alongside progress on two clinical programmes for exaluren in rare kidney diseases caused by nonsense mutations.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Eloxx Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Eloxx Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →